Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

October 12, 2017: By Joan McKenna
Notal Vision's ForeseeHome monitoring device

Notal Vision’s ForeseeHome monitoring device

Notal Vision announced Oct. 5 that patients have used its ForeseeHome monitoring device 3 million times.

It is the first US FDA-cleared home monitoring system for patients with intermediate dry age-related macular degeneration (AMD) at risk for developing wet AMD.

The self-administered test is designed to detect wet AMD at an earlier stage, allowing doctors to treat patients sooner in disease progression and possibly prevent loss of sight.

The system received US clearance in December 2009 and was used in clinical research before being commercially launched in October 2013. It gained Medicare reimbursement in 2016.

In 2010, the National Eye Institute began using the ForeseeHome in a secondary study to AREDS2 in 1,500 patients. Ninety percent of patients who used the device twice weekly and progressed to wet AMD maintained 20/40 or better vision, compared with 62 percent of patients whose diagnosis was during a routine eye exam or visit triggered by symptoms.

Notal Vision is headquartered in Tel Aviv, Israel, with a US office and distribution center in Virginia.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022